ARTICLE | Clinical News
Emricasan: Additional Phase II data
May 4, 2015 7:00 AM UTC
Additional data from a double-blind, U.S. Phase II trial in 38 patients with NAFLD, including patients with non-alcoholic steatohepatitis (NASH), showed that twice-daily 25 mg emricasan led to a media...